

ROGO 217 US (10309708)REMARKS

The courtesies extended to the undersigned and co-inventor Thomas Parker are appreciated. The telephone interview is believed to have been very helpful in resolving the issues in this case.

With respect to the spelling issues, iminothiolane in intended, throughout the specification and claims. Aminothiolane was introduced into the claims inadvertently. The present amendment addresses this.

Amended claim 10 refers to "said" ligand, obviating the rejection under 35 U.S.C. § 112.

Also, claim 17, presented previously, is incorporated into claim 10. This eliminates the issues with respect to Pope, since Pope was only used to reject unamended claim 10.

Bieniarz would remain an issue, except that as discussed during the interview, Bieniarz does not teach the attachment of iminothiolane in a solution of DMF. Example 16 does not so state. Example 16 states that the antibody containing complex is introduced in DMF, but not the iminothiolane. There is actually no teaching whatsoever regarding the use of DMF with iminothiolane.

For anticipation to lie, each and every element of the claimed invention must be taught in a single reference. Such is not the case here. As such, the rejection should be withdrawn.


The secondary references do not obviate this failing, and as such their citation does not remediate the rejection.

In view of the forgoing, allowance of claim 10-14, and 18 is believed proper, and is urged.

ROGO 217 US (10309708)

No fee is believed due, however, should a fee become due the Commissioner is hereby authorized to deduct any fee from Deposit Account No. 50-0624.

Respectfully submitted,



By  
Norman D. Hanson  
Registration No.: 30,946  
FULBRIGHT & JAWORSKI L.L.P.  
666 Fifth Avenue  
New York, New York 10103  
(212) 318-3000  
(212) 318-3400 (Fax)  
Attorney for Applicant